- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03170622
Evaluation of Faecal Volatile Organic Compounds in the Diagnosis of Paediatric Inflammatory Bowel Disease (VOCs)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Inflammatory bowel disease (IBD) is a growing and significant problem in childhood. The diagnosis and monitoring of IBD in children is highly invasive and is accompanied by risk, stress/anxiety for children and families and significant use of healthcare resources. Children, young people and families have told investigators that a non-invasive diagnostic test is a priority for the NHS.
IBD is an incurable chronic, relapsing condition of unknown aetiology. Its frequency has increased markedly across the world in recent years with the highest prevalence reported in Europe (322/100,000 population for CD; 505/100,000 for UC). A marked increased incidence has been seen in children especially in the Northern Hemisphere and largely due to an increase in Crohn's disease. Up to 25% of IBD starts in childhood or adolescence.
Early-onset IBD, possibly due to inheritance of a greater number of susceptibility genes and/or earlier exposure to environmental triggers, differs from that occurring in adults. In children, inflammation occurs most commonly in the colon complicating differentiation between CD and UC. Early-onset CD is more common in boys (whereas adult-onset disease occurs more commonly in females) and tends to be more extensive with greater involvement of the upper intestine. Colonic inflammation in children with UC also tends to be more extensive than in adults.
At initial presentation in all suspected children, upper and lower intestinal endoscopy (requiring two days of bowel cleansing and usually a general anaesthetic) and small bowel imaging by magnetic resonance enterography or wireless capsule endoscopy are required. Although serious adverse events are uncommon, these invasive investigations are highly stressful for children and their families and consume considerable hospital resources. Undertaking these investigations delays diagnosis and the start of treatment.
Accurate, non-invasive, rapid and cost-effective diagnostic tools that can be used in the clinic or ward setting and better means of differentiating CD from UC are needed. Faecal calprotectin (FC), a non-specific marker of intestinal inflammation, is recommended by NICE to distinguish IBD from non-inflammatory gut disorders such as irritable bowel syndrome (https://www.nice.org.uk/guidance/dg11) and a near-patient test has been developed (http://www.buhlmannlabs.ch/core/quantum-blue/calprotectin/). A recent meta-analysis (394 IBD/321 non-IBD controls) reported a pooled sensitivity and specificity of FC in the diagnosis of IBD in children of 0.98 (95% confidence interval: 0.95-1.0) and 0.68 (0.50- 0.86) respectively. The low specificity indicates that an alternative or additional test with higher specificity is needed to reduce the time to diagnosis and avoid many children undergoing unnecessary investigations.
There is great interest in the measurement of volatile organic compounds (VOCs) in breath and vapours from various human tissues (urine, stool, blood) in the diagnosis and monitoring of a wide range of diseases. VOCs emitted from stool are responsible for stool odour and consist of a large number of carbon based molecules of low molecular mass (<1.5Kd) including organic acids, alcohols, esters, heterocyclic compounds, aldehydes, ketones and alkanes. They result from the metabolism of the intestinal mucosa and the gut microbiota and their abundance changes according to the specific effects of intestinal diseases on these processes.
Investigators have demonstrated that faecal VOCs are relatively stable over time within and between individuals despite day-to-day variation in diet and are not affected by freezing and storage of stool samples. We have optimized procedures for stool handling for metabolite extraction for gas chromatography-mass spectrometry (GC-MS) analysis (sample volume, solid phase micro-extraction fibre coating, extraction conditions [temperature and time] and vial volume and also developed the advanced statistical methods required for determining and comparing VOC profiles.
Investigators have shown that the analysis of VOCs separates adult patients with diarrhoea-predominant irritable bowel syndrome (n=30) from those with active CD (62) and UC (n=48; sensitivity of 94% and 96% and specificity of 82% and 80% respectively; p<0.05). Our data in adults strongly suggests that VOCs differentiate CD from UC, and also Crohn's colitis from UC (Ahmed 2013). More recently, research has shown that VOCs also distinguish between active and inactive CD and UC in adult patients (Ahmed 2016).
Despite these encouraging findings, given the differences in IBD between adults and children and that gut microbiota changes with age, it cannot be assumed that diagnostic tests that are effective in adults will necessarily work in children. Therefore, this technology needs to be tested in children. In a proof of principle study, faecal VOCs differentiated children with IBD from healthy children both during active disease and remission. However, investigators are not aware of any previous studies in children that have evaluated the utility of faecal VOCs in differentiating IBD from other common gastrointestinal disorders in an out-patient setting or in monitoring response to treatment.
Measurement of VOCs in fresh stool samples using bench-top equipment in the clinic or ward will be possible in the near future. The University of Liverpool owns the intellectual property for the development of a point-of-care instrument. The development of this technology is supported by the University of Liverpool and Cancer Research UK (the latter for measurement of VOCs in urine to detect bladder and prostate cancer). Industrial partners are engaged in refining the prototype ready for moulding and production this year. The aim is to have a fully tested, CE marked, point-of-care instrument on sale in the EU for bladder and prostate cancer in 2020/1 and for IBD/irritable bowel syndrome in 2022.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Stephen Allen
- Phone Number: 0151 228 4811
- Email: Stephen.Allen@lstmed.ac.uk
Study Contact Backup
- Name: Lucy Cooper
- Phone Number: 01512525570
- Email: lucy.cooper@alderhey.nhs.uk
Study Locations
-
-
Merseyside
-
Liverpool, Merseyside, United Kingdom, L12 2AP
- Alder Hey Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Children (age <18 years) capable of giving informed consent, or if age < 16 years or not capable of giving consent, with an acceptable individual capable of giving consent on the child's behalf
Children of either gender attending a paediatric gastroenterology referral clinic in whom IBD is suspected following initial clinical assessment
Further evaluation planned to diagnose the cause of the child's illness
Willing for demographic and clinical information to be used for the purposes of the study
Willing for part of the stool sample provided for routine clinical assessment to be used for the measurement of VOCs
Exclusion Criteria:
Treatment already received for IBD (e.g. polymeric formula feeds in children awaiting investigation)
Established diagnosis of a significant gut disorder (e.g. short bowel syndrome)
Failure to obtain informed consent from the young person or parent/guardian
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
IBD
Children (age <18 years) attending clinics in 3 paediatric gastroenterology referral centres in the UK in whom clinical assessment indicates that IBD is a possibility
|
This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
VOCs
Time Frame: Visit 1-1day
|
For the VOCS identified by GCMS, consistent with our findings in adults (Ahmed 2016), we anticipate identifying a small number of VOCs that can be used to diagnose IBD and distinguish IBD from other common pathologies including functional abdominal conditions. For the results generated by the GC-sensor (Odoreader©), we will compare the faecal VOC profile in children in whom IBD is confirmed with that in children with alternative diagnoses according to the advanced statistical methods required for determining and comparing VOC profiles. |
Visit 1-1day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Underlying disease
Time Frame: Visit 1-1 day
|
Similar analyses as for the primary outcome will be used for the secondary outcomes.
To shed light on underlying disease mechanisms in pIBD and other common conditionse will use existing KEGG databases to determine the source of faecal VOCs identified by GCMS, which will include bacteria, fungi, host tissues and metabolism (http://www.genome.jp/kegg/kegg2.html).
|
Visit 1-1 day
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sub-group analysis
Time Frame: Visit 1-1 day
|
We will fully explore the data from our non-IBD children to identify characteristic faecal VOC profiles in common diagnostic groups (e.g.
functional abdominal pain, coeliac disease) and also demographic and environmental factors (e.g.
age, sex, diet) using the approaches described above.
|
Visit 1-1 day
|
Collaborators and Investigators
Investigators
- Study Director: Lucy Cooper, Alder Hey Children's NHS Trust
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 223199
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Intervention group
-
Muğla Sıtkı Koçman UniversityNot yet recruiting
-
University of LiegeCentre Hospitalier Universitaire de Liege; Bial Foundation; FNRS (Télévie); Fondation...RecruitingPain | Cancer | Fatigue | Cognitive Impairment | Sleep Disturbance | Distress, EmotionalBelgium
-
Hospital de Clinicas de Porto AlegreUnknown
-
University of California, San FranciscoNational Cancer Institute (NCI); Cancer Prevention Institute of CaliforniaCompletedHereditary Breast and Ovarian Cancer Syndrome
-
University of Sao PauloCompletedAnxiety | Self Esteem
-
Haute Ecole de Santé VaudCompletedArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSwitzerland
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases
-
Azienda Ospedaliero-Universitaria CareggiRecruiting
-
University of OxfordOxford Brookes UniversityRecruitingOverweight/Obesity, AdolescentUnited Kingdom
-
Beijing Tsinghua Chang Gung HospitalRecruitingLifestyle Intervention | Non Communicable DiseasesChina